scholarly journals Decreased expression of COLEC10 predicts poor overall survival in patients with hepatocellular carcinoma

2018 ◽  
Vol Volume 10 ◽  
pp. 2369-2375 ◽  
Author(s):  
Baozhu Zhang ◽  
Haibo Wu
Keyword(s):  
Hepatocellular Carcinoma ◽  
Overall Survival ◽  
Poor Overall Survival

Low expression of CD112 is associated with poor overall survival in patients with hepatocellular carcinoma

2014 ◽  
Vol 45 (9) ◽  
pp. 1944-1950 ◽  
Author(s):  
Xiaojun Huang ◽  
Ping Qu ◽  
Yibing Chen ◽  
Xingchun Zhou ◽  
Yousheng Wu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Overall Survival ◽  
Poor Overall Survival ◽  
Low Expression

scholarly journals MLH1 single-nucleotide variant in circulating tumor DNA predicts overall survival of patients with hepatocellular carcinoma

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Soon Sun Kim ◽  
Jung Woo Eun ◽  
Ji-Hye Choi ◽  
Hyun Goo Woo ◽  
Hyo Jung Cho ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Overall Survival ◽  
Circulating Tumor Dna ◽  
Single Nucleotide Variants ◽  
Poor Overall Survival ◽  
Single Nucleotide ◽  
Strong Basis ◽  
Polymerase Chain ◽  
Digital Polymerase Chain Reaction ◽  
Tumor Dna

Abstract Liquid biopsy can provide a strong basis for precision medicine. We aimed to identify novel single-nucleotide variants (SNVs) in circulating tumor DNA (ctDNA) in patients with hepatocellular carcinoma (HCC). Deep sequencing of plasma-derived ctDNA from 59 patients with HCC was performed using a panel of 2924 SNVs in 69 genes. In 55.9% of the patients, at least one somatic mutation was detected. Among 25 SNVs in 12 genes, four frequently observed SNVs, MLH1 (13%), STK11 (13%), PTEN (9%), and CTNNB1 (4%), were validated using droplet digital polymerase chain reaction with ctDNA from 62 patients with HCC. Three candidate SNVs were detected in 35.5% of the patients, with a frequency of 19% for MLH1 chr3:37025749T>A, 11% for STK11 chr19:1223126C>G, and 8% for PTEN chr10:87864461C>G. The MLH1 and STK11 SNVs were also confirmed in HCC tissues. The presence of the MLH1 SNV, in combination with an increased ctDNA level, predicted poor overall survival among 107 patients. MLH1 chr3:37025749T>A SNV detection in ctDNA is feasible, and thus, ctDNA can be used to detect somatic mutations in HCC. Furthermore, the presence or absence of the MLH1 SNV in ctDNA, combined with the ctDNA level, can predict the prognosis of patients with HCC.

Associations between high levels of Notch1 expression and high invasion and poor overall survival in hepatocellular carcinoma

Tumor Biology ◽  
2012 ◽  
Vol 34 (1) ◽  
pp. 543-553 ◽  
Author(s):  
Liang Zhou ◽  
Ning Zhang ◽  
Qing-jun Li ◽  
Wei Sun ◽  
Yong Zhang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Overall Survival ◽  
Poor Overall Survival

scholarly journals Downregulation of CYP39A1 Serves as a Novel Biomarker in Hepatocellular Carcinoma with Worse Clinical Outcome

2021 ◽  
Vol 2021 ◽  
pp. 1-18
Author(s):  
Dan Li ◽  
Tao Yu ◽  
Junjie Hu ◽  
Jie Wu ◽  
Shi Feng ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Overall Survival ◽  
Cell Growth ◽  
Protein Expression ◽  
Cell Viability ◽  
Suppressor Gene ◽  
Metabolic Enzyme ◽  
Poor Overall Survival ◽  
Mrna And Protein Expression ◽  
Growth Changes

Background. CYP39A1 is a poorly characterized metabolic enzyme that has been investigated in a few tumors. However, the role of CYP39A1 in hepatocellular carcinoma (HCC) has not yet been clarified. In this study, the expression and clinical significance of CYP39A1 in HCC were explored. Methods. CYP39A1 protein expression was detected in Akt/c-Met-induced HCC mice and 14 paired fresh HCC samples as well as another 159 HCC and matched noncancerous tissues. Meanwhile, the mRNA expression was analyzed by GEO and TCGA analysis and validated in 14 paired fresh HCC tissues. Furthermore, the relationships between CYP39A1 expression and clinicopathologic features as well as prognosis were analyzed. HCC cell growth changes were analyzed by cell viability assays after CYP39A1 overexpression and then validated after CYP39A1 knockout by DepMap database analysis. Results. CYP39A1 protein expression was lower expressed in HCC mouse models, and its mRNA and protein expression were also downregulated in HCC compared with noncancerous liver tissues. Higher CYP39A1 expression was associated with well differentiation. Moreover, survival analysis indicated that lower CYP39A1 expression was associated with poorer overall survival. In addition, HepG2 and SMMC-7721 cell viability were inhibited after CYP39A1 overexpression. Genome-wide CRISPR/Cas9 proliferation screening indicated that knockout of CYP39A1 could promote HCC cell growth. Likewise, p-NF-κB and Nrf2 were suppressed after CYP39A1 overexpression. It is worth mentioning that total bile acid, total bilirubin, and direct bilirubin were significantly increased in the patients with low CYP39A1 expression. Conclusions. Downregulation of CYP39A1 is associated with HCC carcinogenesis, tumor differentiation, and poor overall survival, suggesting that CYP39A1 may serve as a tumor suppressor gene and novel biomarker for HCC patients.

scholarly journals High levels of EphA3 expression are associated with high invasive capacity and poor overall survival in hepatocellular carcinoma

2013 ◽  
Vol 30 (5) ◽  
pp. 2179-2186 ◽  
Author(s):  
CHENG-YI LU ◽  
ZHAO-XU YANG ◽  
LIANG ZHOU ◽  
ZHI-ZHONG HUANG ◽  
HONG-TAO ZHANG ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Overall Survival ◽  
Poor Overall Survival ◽  
Invasive Capacity

scholarly journals Increased expression of HOXB9 in hepatocellular carcinoma predicts poor overall survival but a beneficial response to sorafenib

2017 ◽  
Vol 37 (4) ◽  
pp. 2270-2276 ◽  
Author(s):  
Naokazu Chiba ◽  
Yosuke Ozawa ◽  
Kosuke Hikita ◽  
Masaaki Okihara ◽  
Toru Sano ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Overall Survival ◽  
Poor Overall Survival ◽  
Beneficial Response

Value of HCC-MELD Score in Patients With Hepatocellular Carcinoma Undergoing Liver Transplantation

2017 ◽  
Vol 28 (1) ◽  
pp. 63-69 ◽  
Author(s):  
Gian Piero Guerrini ◽  
Domenico Pinelli ◽  
Elena Marini ◽  
Vittorio Corno ◽  
Michela Guizzetti ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplantation ◽  
Overall Survival ◽  
Cox Regression ◽  
Prognostic Score ◽  
Disease Free Survival ◽  
Meld Score ◽  
Poor Overall Survival ◽  
Cox Regression Analysis ◽  
Improve Risk Stratification

Context: Liver transplantation (LT) is considered the ideal therapy for patients with hepatocellular carcinoma (HCC) having cirrhosis but the shortage of liver donors and the risk of dropout from the wait list due to tumor progression severely limit transplantation. A new prognostic score, the HCC-model for end-stage liver disease (HCC-MELD), was developed by combining α-fetoprotein (AFP), MELD, and tumor size, to improve risk stratification of dropout in patients with HCC. Objectives: In this study, we investigated the ability of the HCC-MELD score in predicting the posttransplant for patients fulfilling Milan criteria (MC). Design: Two hundred patients with stage II tumor were retrospectively reviewed from a total of 1290 transplants performed at our institution from October 1997 through April 2015. Cox regression analysis was performed to identify the prognostic factors impacting the posttransplant survival. Results: Overall survival at 1, 5, and 10 years was 89.3%, 71.1%, and 67.2%, whereas disease-free survival was 86.4%, 66.5%, and 52.4%, respectively. Multivariate analysis showed HCC-MELD score (hazard ratio [HR] 39.6, P < .001) and microvascular invasion (HR 2.41, P = .002) to be independent risk factors for recurrence, whereas HCC diameter (HR 1.15, P = .041), HCC-MELD (HR 15.611, P = .006), and grading (HR 2.17, P = .03) proved to be predictive factors of poor overall survival. Conclusion: Our study showed the validity of the HCC-MELD equation in the evaluation of patients undergoing LT for HCC. This score offers a reliable method to assess the risk of waiting list dropout and predict posttransplantation outcomes.

scholarly journals High SGO2 Expression Predicts Poor Overall Survival: A Potential Therapeutic Target for Hepatocellular Carcinoma

Genes ◽  
2021 ◽  
Vol 12 (6) ◽  
pp. 876
Author(s):  
Min Deng ◽  
Shaohua Li ◽  
Jie Mei ◽  
Wenping Lin ◽  
Jingwen Zou ◽  
...  
Keyword(s):  
Gene Expression ◽  
Hepatocellular Carcinoma ◽  
Overall Survival ◽  
Therapeutic Target ◽  
Tumor Grade ◽  
The Cancer Genome Atlas ◽  
High Expression ◽  
Clinicopathological Parameters ◽  
Potential Therapeutic Target ◽  
Poor Overall Survival

Shugoshin2 (SGO2) may participate in the occurrence and development of tumors by regulating abnormal cell cycle division, but its prognostic value in hepatocellular carcinoma (HCC) remains unclear. In this study, we accessed The Cancer Genome Atlas (TCGA) database to get the clinical data and gene expression profile of HCC. The expression of SGO2 in HCC tissues and nontumor tissues and the relationship between SGO2 expression, survival, and clinicopathological parameters were analyzed. The SGO2 expression level was significantly higher in HCC tissues than in nontumor tissues (p < 0.001). An analysis from the Oncomine and Gene Expression Profiling Interactive Analysis 2 (GEPIA2) databases also demonstrated that SGO2 was upregulated in HCC (all p < 0.001). A logistic regression analysis revealed that the high expression of SGO2 was significantly correlated with gender, tumor grade, pathological stage, T classification, and Eastern Cancer Oncology Group (ECOG) score (all p < 0.05). The overall survival (OS) of HCC patients with higher SGO2 expression was significantly poor (p < 0.001). A multivariate analysis showed that age and high expression of SGO2 were independent predictors of poor overall survival (all p < 0.05). Twelve signaling pathways were significantly enriched in samples with the high-SGO2 expression phenotype. Ten proteins and 34 genes were significantly correlated with SGO2. In conclusion, the expression of SGO2 is closely related to the survival of HCC. It may be used as a potential therapeutic target and prognostic marker of HCC.

Sign in / Sign up

Export Citation Format

Share Document